Skip to content

Network of Cancer Research

Reliable, unbiased and up to date information in cancer research

Network of Cancer Research

Reliable, unbiased and up to date information in cancer research

  • Home
  • About
    • Home
    • BET
Leukemia

SIM1 is a PROTAC Based BET Family Degrader

Louis Gilman August 11, 2021

Proteolytic targeting chimera (PROTAC) is a heterobifunctional small molecule that acts by inducing selective intracellular proteolysis. Specifically, bifunctional PROTAC molecule is including ligands of target protein (POI) and covalent ligands…

Prostate Cancer

ABBV-744 is a First-in-Class, Orally Active and Selective BET BDII Inhibitor

Louis Gilman July 20, 2021

The proteins of BET (bromodomain and extra-terminal) domain family are epigenetic readers. BET domain family proteins bind acetylated histones through their bromodomains to regulate gene transcription. BET domain family proteins…

Cancer

GSK973 is a Highly Selective BET BD2 Inhibitor

Louis Gilman May 19, 2021

The bromodomain and extra-terminal (BET) family of proteins are epigenetic readers of chromatin. The two tandem bromodomains (BD1 and BD2) of each of the four proteins (BRD2, 3, 4, and…

Melanoma

NHWD-870 is an Orally Active and Selective BET Bromodomain Inhibitor

Louis Gilman January 9, 2021

Brominedomain can recognize acetylated lysine residues. As the "reader" of lysine acetylation, the bromine domain is responsible for the transduction of signals carried by acetylated lysine residues and transforming them…

Cancer

GNE-371, a Chemical Probe for the Second Bromodomains of TFIID Subunit 1 and TFIID Subunit 1-Like

Louis Gilman December 9, 2020

Bromodomains are protein modules that serve as epigenetic readers. These modules consist of 110 amino acids, specifically recognize acetylated lysine residues on histone tails. They also play important roles in…

Lymphoma Solid Tumors

CC-90010 is a Reversible and Orally Active BET Inhibitor

Louis Gilman December 8, 2020

Come straight to the point, CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors. The bromodomain and extra-terminal…

Leukemia PROTAC

GNE-987, a BET PROTAC Degrader, is a Part of PROTAC-Antibody (CLL1) Conjugate for ADC

Louis Gilman November 21, 2020

BRD4 is a member of the BET family of proteins (BRD2, 3, 4, and T). It functions as an epigenetic “reader” of acetylated histone lysine residues via its two bromodomain…

Leukemia

BETd-260 is a Potent PROTAC BET Degrader

Louis Gilman November 18, 2020

The bromodomain and extra-terminal (BET) family proteins consist of BRD2, BRD3, BRD4, and testis-specific BRDT members. They are epigenetic “readers” and play a key role in the regulation of gene…

NUT midline carcinoma Prostate Cancer Squamous Carcinoma

NEO2734 is an Orally Active Dual p300/CBP and BET Bromodomain Selective Inhibitor

Louis Gilman October 15, 2020

NUT midline carcinoma (NMC) is a rare, aggressive subtype of squamous carcinoma. This kind of cancer is usually driven by BRD4-NUT fusion oncoprotein. BRD4, a BET protein, binds to chromatin…

Lymphoma Mantle Cell Lymphoma

GSK778 is a Potent and Selective Inhibitor of BET BD1

Louis Gilman July 30, 2020

The bromodomain is a protein domain of about 110 amino acids, which can recognize acetylated lysine residues. Specifically, the bet (Bromo- and terminal domain) family consists of germ cell-specific (BRDT)…

Posts navigation

1 2 3

Next Page »

Recent Posts

  • BI 7446 is a STING Agonist for Immuno-oncology Research
  • JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research
  • OATD-02 is an Orally Active Arginase 1/2 Inhibitor for Melanoma Research
  • INCB086550 is an Orally Active PD-L1 Inhibitor for Multiple Cancers Research
  • Panobinostat is a HDAC Inhibitor for Multiple Myeloma Research

Archives

  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019

Categories

  • Abdominal Aortic Aneurysm
  • Acute Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Adenoid Cystic Carcinoma
  • Adenomyosis
  • Adrenocortical carcinoma
  • Adult T-cell leukemia/lymphoma
  • Anti-angiogenic
  • anti-inflammatory
  • antioxidant
  • autoimmune disease
  • B-cell malignancies
  • Bladder Cancer
  • Bone Cancer
  • Brain Cancer
  • Breast Cancer
  • Cancer
  • Cancer Metastases
  • Castration Resistant Prostate Cancer
  • ccRCC
  • Cervical Cancer
  • Cervix Cancer
  • Chemotherapy
  • Chemotherapy Side Effects
  • Cholangiocarcinoma
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Colon Adenocarcinoma
  • Colon Cancer
  • Colorectal Cancer
  • Colorectal Cancer
  • Endometrial Adenocarcinoma
  • Endometrial Cancer
  • ER+ Breast Cancer
  • Esophageal Squamous Cell Carcinoma
  • Esophagus Cancer
  • Ewing's Sarcoma
  • Fibrosarcoma
  • Follicular Lymphoma
  • Gastric Adenocarcinoma
  • Gastric Cancer
  • Gastrointestinal Stromal Tumor
  • Glioblastoma
  • Glioblastoma Multiforme
  • Gliocytoma
  • Glioma
  • Head & Neck Cancer
  • Head and Neck Cancer
  • Hematologic Neoplasms
  • Hematological Malignancies
  • Hepatocellular carcinoma
  • HER2+ Breast Cancer
  • Hodgkin Lymphoma
  • HPV
  • HSV-1
  • Idiopathic Pulmonary Fibrosis
  • Kaposi's Sarcoma
  • Kidney Cancer
  • Large B Cell Lymphoma
  • Large B-cell Lymphoma
  • Large Cell Lung Cancer
  • Leukemia
  • Liver Cancer
  • Lung Adenocarcinoma
  • Lung Cancer
  • Lymphoma
  • Malaria
  • Mantle Cell Lymphoma
  • Medullary Thyroid Carcinoma
  • Medulloblastoma
  • Medulloblastomas
  • Megakaryoblastic Leukemia
  • Melanoma
  • Mesothelioma
  • Metabolism
  • Metabolism-related diseases
  • Metastatic Castration-resistant Prostate Cancer
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndrome
  • Myeloma
  • Nasopharyngeal Carcinoma
  • Neoplasms
  • Neuroblastoma
  • Neuroendocrine Tumors
  • Neuropathy
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • NSCLC
  • NUT midline carcinoma
  • Obesity
  • Oesophageal Cancer
  • Oral Carcinoma
  • Osteosarcoma
  • Ovary Cancer
  • Pancreas Cancer
  • Pancreatic cancer
  • Pancreatic Ductal Adenocarcinoma
  • Ph+ ALL
  • Philadelphia-positive Leukemias
  • Plasmacytoma
  • Prostate Cancer
  • PROTAC
  • Renal Carcinoma
  • Sarcoma
  • Skin Cancer
  • Small Cell Lung Cancer
  • Soft Tissue Tumor
  • Solid Tumors
  • Squamous Carcinoma
  • T Acute Lymphoblastic Leukemia
  • T-cell Lymphoma
  • Thyroid Cancer
  • Triple-Negative Breast Cancer
  • uncategorized
  • Uterine Serous Carcinoma

You Missed

Breast Cancer

BI 7446 is a STING Agonist for Immuno-oncology Research

Gastric Cancer Obesity

JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research

Multiple Myeloma Myeloma

OATD-02 is an Orally Active Arginase 1/2 Inhibitor for Melanoma Research

autoimmune disease

INCB086550 is an Orally Active PD-L1 Inhibitor for Multiple Cancers Research

Network of Cancer Research

Reliable, unbiased and up to date information in cancer research

Copyright © All rights reserved | Blogus by Themeansar.